|Bid||137.63 x 1000|
|Ask||137.77 x 800|
|Day's Range||137.21 - 138.65|
|52 Week Range||96.99 - 140.53|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||0.96 (0.70%)|
|1y Target Est||148.08|
Let's talk about the popular Zimmer Biomet Holdings, Inc. (NYSE:ZBH). The company's shares received a lot of attention...
WARSAW, Ind., Aug. 16, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced U.S. Food and Drug Administration approval for The Tether™ for treatment of scoliosis, providing a fusion-less alternative for young patients requiring surgery. The current surgical treatment for scoliosis is an invasive operation involving large incisions, extensive soft tissue disruption and restriction of spinal motion with metal rods inserted along both sides of the spine to secure and align the vertebrae. Surgeons have tirelessly searched for alternative non-fusion surgical approaches to address scoliosis without limiting the skeletal development of these patients who are active and still growing. Zimmer Biomet's anterior vertebral body tethering (AVBT) solution, The Tether, uses a strong, flexible cord, rather than metal rods, to pull on the outside of a scoliosis curve to initially straighten the spine, while the inside of the curve is left free to grow.
WARSAW, Ind. , Aug. 15, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the Morgan Stanley 17 th Annual Global ...
WARSAW, Ind. , Aug. 13, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the Wells Fargo Securities 2019 Healthcare ...
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
The sale of an orthopedic medical device boosted the bottom line of the state’s largest health care system, contributing to one of the highest operating margins the organization has experienced in years.
Zimmer Biomet (ZBH) is a leader in orthopedic medicine. Products and solutions are used to treat patients suffering from disorders or injuries to bones, joints, or supporting soft tissues, explains Chuck Carlson, dividend reinvestment specialist and editor of DRIP Investor.
WARSAW, Ind., July 26, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC) to purchase up to one million shares of Zimmer Biomet common stock, or approximately 0.49 percent of the Company's outstanding shares as of the offer date of July 15, 2019, at a price of $115.35 per share in cash. TRC's offer price is approximately 4.4 percent lower than the $120.60 closing price of the Company's common stock on July 12, 2019, the last trading day before commencement of the offer, and approximately 14.2 percent lower than the $134.50 closing price of the Company's common stock on July 26, 2019. Zimmer Biomet does not endorse TRC's unsolicited mini-tender offer and recommends that shareholders not tender their shares in response to the offer.
Zimmer Biomet Holdings Inc (NASDAQ: ZBH ) reported quarterly earnings of $1.93 per share, which beat the analyst consensus estimate of $1.91. This is a 0.52% increase over earnings of $1.92 per share from ...
Zimmer (ZBH) delivered earnings and revenue surprises of 0.52% and 0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of orthopedic device maker Zimmer Biomet jump after the company reports second-quarter earnings and sales that beat analysts' forecasts.
- Net sales of $1.989 billion for the second quarter represent a decrease of 0.9% from the prior year period; an increase of 1.2% on a constant currency basis - Diluted earnings per share for the second ...
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a large-cap worth US$25b, comes to mind for investors seeking a strong and...
Zimmer Biomet Holdings Inc NYSE:ZBHView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.04 billion over the last one-month into ETFs that hold ZBH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. ZBH credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.